recombinant von Willebrand factor (Vonvendi)

From Aaushi

Jump to navigation Jump to search

^[1]

Indications

as needed treatment & control of bleeding episodes in adults with von Willebrand disease

Adverse effects

generalized pruritus

More general terms

References

↑ FDA News Release. December 8, 2015 FDA approves first recombinant von Willebrand factor to treat bleeding episodes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476065.htm

Retrieved from "https://aaushi.info/w/index.php?title=A50459&oldid=1115942"

↑ Back to top